Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy

Background: Oral mucositis (OM) is a common toxic side effect in nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) that has a negative impact on treatment outcomes and patients’ survival. Our study aimed to evaluate the impact of parenteral glutamine supplement (d...

Full description

Bibliographic Details
Main Authors: Chih-Chun Wang, Tzer-Zen Hwang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Shyh-An Yeh, Meng-Che Hsieh
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/14/5/997
_version_ 1797474146138980352
author Chih-Chun Wang
Tzer-Zen Hwang
Chuan-Chien Yang
Ching-Feng Lien
Chien-Chung Wang
Yu-Chen Shih
Shyh-An Yeh
Meng-Che Hsieh
author_facet Chih-Chun Wang
Tzer-Zen Hwang
Chuan-Chien Yang
Ching-Feng Lien
Chien-Chung Wang
Yu-Chen Shih
Shyh-An Yeh
Meng-Che Hsieh
author_sort Chih-Chun Wang
collection DOAJ
description Background: Oral mucositis (OM) is a common toxic side effect in nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) that has a negative impact on treatment outcomes and patients’ survival. Our study aimed to evaluate the impact of parenteral glutamine supplement (dipeptiven) on oncologic outcomes in patients with NPC treated with CCRT. Methods: Patients who were diagnosed with pathologically proved NPC and treated with CCRT were enrolled into our study. Patients were classified as dipeptiven (+) and dipeptiven (–). Oncologic outcomes were measured, and multivariate regression analysis was performed. Grade 3–4 treatment related toxicities were also documented. Results: A total of 144 patients with NPC were recruited in this study to evaluate oncologic outcomes, with 41 dipeptiven (+) and 103 dipeptiven (–). CCRT interruption rate and severe adverse effect (SAE) rate were significant lower in the dipeptiven (+) group than in the dipeptiven (–) group. The median overall survival (OS) was not mature yet in the dipeptiven (+) group and 30 months in the dipeptiven (–) group (<i>p</i> < 0.01). Multivariate analysis demonstrated that dipeptiven supplementation and CCRT interruption were independent predictors associated with better survival. The OS was longest in patients with a dipeptiven supplement and patients who had CCRT interruption had significantly worst OS. As for safety profiles, grade 3 to 4 adverse effects were fewer in dipeptiven (+) than in dipeptiven (–). Conclusion: Dipeptiven supplementation is crucial in NPC patients treated with CCRT, which can ameliorate treatment-related toxicity and augment treatment efficacy. Further prospective clinical trials are warranted to validate our results.
first_indexed 2024-03-09T20:26:59Z
format Article
id doaj.art-29ba6c50f0074c6687c97587d3fc0773
institution Directory Open Access Journal
issn 2072-6643
language English
last_indexed 2024-03-09T20:26:59Z
publishDate 2022-02-01
publisher MDPI AG
record_format Article
series Nutrients
spelling doaj.art-29ba6c50f0074c6687c97587d3fc07732023-11-23T23:32:58ZengMDPI AGNutrients2072-66432022-02-0114599710.3390/nu14050997Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent ChemoradiotherapyChih-Chun Wang0Tzer-Zen Hwang1Chuan-Chien Yang2Ching-Feng Lien3Chien-Chung Wang4Yu-Chen Shih5Shyh-An Yeh6Meng-Che Hsieh7Department of Otolaryngology, E-Da Hospital, Kaohsiung 82445, TaiwanDepartment of Otolaryngology, E-Da Hospital, Kaohsiung 82445, TaiwanDepartment of Otolaryngology, E-Da Hospital, Kaohsiung 82445, TaiwanDepartment of Otolaryngology, E-Da Hospital, Kaohsiung 82445, TaiwanDepartment of Otolaryngology, E-Da Hospital, Kaohsiung 82445, TaiwanCollege of Medicine, I-Shou University, Kaohsiung 82445, TaiwanCollege of Medicine, I-Shou University, Kaohsiung 82445, TaiwanCollege of Medicine, I-Shou University, Kaohsiung 82445, TaiwanBackground: Oral mucositis (OM) is a common toxic side effect in nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) that has a negative impact on treatment outcomes and patients’ survival. Our study aimed to evaluate the impact of parenteral glutamine supplement (dipeptiven) on oncologic outcomes in patients with NPC treated with CCRT. Methods: Patients who were diagnosed with pathologically proved NPC and treated with CCRT were enrolled into our study. Patients were classified as dipeptiven (+) and dipeptiven (–). Oncologic outcomes were measured, and multivariate regression analysis was performed. Grade 3–4 treatment related toxicities were also documented. Results: A total of 144 patients with NPC were recruited in this study to evaluate oncologic outcomes, with 41 dipeptiven (+) and 103 dipeptiven (–). CCRT interruption rate and severe adverse effect (SAE) rate were significant lower in the dipeptiven (+) group than in the dipeptiven (–) group. The median overall survival (OS) was not mature yet in the dipeptiven (+) group and 30 months in the dipeptiven (–) group (<i>p</i> < 0.01). Multivariate analysis demonstrated that dipeptiven supplementation and CCRT interruption were independent predictors associated with better survival. The OS was longest in patients with a dipeptiven supplement and patients who had CCRT interruption had significantly worst OS. As for safety profiles, grade 3 to 4 adverse effects were fewer in dipeptiven (+) than in dipeptiven (–). Conclusion: Dipeptiven supplementation is crucial in NPC patients treated with CCRT, which can ameliorate treatment-related toxicity and augment treatment efficacy. Further prospective clinical trials are warranted to validate our results.https://www.mdpi.com/2072-6643/14/5/997nasopharyngeal carcinomachemoradiotherapyglutaminedipeptivenoncologic outcomesoral mucositis
spellingShingle Chih-Chun Wang
Tzer-Zen Hwang
Chuan-Chien Yang
Ching-Feng Lien
Chien-Chung Wang
Yu-Chen Shih
Shyh-An Yeh
Meng-Che Hsieh
Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
Nutrients
nasopharyngeal carcinoma
chemoradiotherapy
glutamine
dipeptiven
oncologic outcomes
oral mucositis
title Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
title_full Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
title_fullStr Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
title_full_unstemmed Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
title_short Impact of Parenteral Glutamine Supplement on Oncologic Outcomes in Patients with Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
title_sort impact of parenteral glutamine supplement on oncologic outcomes in patients with nasopharyngeal cancer treated with concurrent chemoradiotherapy
topic nasopharyngeal carcinoma
chemoradiotherapy
glutamine
dipeptiven
oncologic outcomes
oral mucositis
url https://www.mdpi.com/2072-6643/14/5/997
work_keys_str_mv AT chihchunwang impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT tzerzenhwang impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT chuanchienyang impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT chingfenglien impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT chienchungwang impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT yuchenshih impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT shyhanyeh impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy
AT mengchehsieh impactofparenteralglutaminesupplementononcologicoutcomesinpatientswithnasopharyngealcancertreatedwithconcurrentchemoradiotherapy